Citadel Advisors
ADMA icon

Citadel Advisors’s ADMA Biologics ADMA Stock Holding History

Citadel Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.85M Buy
316,500
+55,200
+21% +$871K ﹤0.01% 5377
2025
Q4 		$4.77M Sell
261,300
-650,900
-71% -$11M ﹤0.01% 4364
2025
Q3 		$13.4M Buy
912,200
+725,100
+388% +$12.4M ﹤0.01% 2847
2025
Q2 		$3.41M Sell
187,100
-20,800
-10% -$424K ﹤0.01% 4757
2025
Q1 		$4.12M Buy
207,900
+4,200
+2% +$72.6K ﹤0.01% 4209
2024
Q4 		$3.49M Sell
203,700
-6,500
-3% -$122K ﹤0.01% 4579
2024
Q3 		$4.2M Buy
210,200
+88,800
+73% +$1.38M ﹤0.01% 4230
2024
Q2 		$1.36M Buy
121,400
+97,600
+410% +$819K ﹤0.01% 6035
2024
Q1 		$157K Buy
23,800
+22,500
+1,731% +$123K ﹤0.01% 10697
2023
Q4 		$5.88K Sell
1,300
-3,600
-73% -$13.3K ﹤0.01% 13394
2023
Q3 		$17.5K Sell
4,900
-6,700
-58% -$25.8K ﹤0.01% 12723
2023
Q2 		$42.8K Sell
11,600
-2,900
-20% -$10.7K ﹤0.01% 11992
2023
Q1 		$48K Sell
14,500
-165,500
-92% -$572K ﹤0.01% 12206
2022
Q4 		$698K Buy
180,000
+57,900
+47% +$179K ﹤0.01% 7550
2022
Q3 		$297K Sell
122,100
-19,400
-14% -$46.5K ﹤0.01% 9602
2022
Q2 		$280K Buy
141,500
+13,900
+11% +$27.3K ﹤0.01% 9946
2022
Q1 		$234K Buy
127,600
+5,200
+4% +$8.11K ﹤0.01% 11150
2021
Q4 		$173K Buy
122,400
+43,000
+54% +$56.5K ﹤0.01% 12066
2021
Q3 		$90K Buy
79,400
+9,100
+13% +$12.7K ﹤0.01% 12972
2021
Q2 		$112K Buy
70,300
+6,300
+10% +$11.1K ﹤0.01% 12815
2021
Q1 		$113K Sell
64,000
-11,500
-15% -$26.3K ﹤0.01% 12359
2020
Q4 		$147K Buy
75,500
+3,700
+5% +$7.78K ﹤0.01% 9957
2020
Q3 		$172K Buy
71,800
+12,900
+22% +$35.4K ﹤0.01% 8922
2020
Q2 		$173K Buy
58,900
+17,000
+41% +$48.8K ﹤0.01% 8638
2020
Q1 		$121K Buy
41,900
+30,800
+277% +$106K ﹤0.01% 8482
2019
Q4 		$44K Sell
11,100
-200
-2% -$872 ﹤0.01% 8786
2019
Q3 		$50K Buy
+11,300
New +$47.2K ﹤0.01% 8699
2019
Q2 		– Sell
-11,300
Closed -$43K – 9095
2019
Q1 		$43K Buy
+11,300
New +$39.9K ﹤0.01% 8878

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citadel Advisors's ADMA Position: Q1 2026 in Review

Citadel Advisors increased its ADMA Biologics (ADMA) stake by 282% in Q1 2026, buying an estimated $67.7M and bringing the position to 5,810,642 shares worth $52.4M. The position accounts for 0.01% of the portfolio, ranked #1316.

Citadel Advisors first reported a position in ADMA in Q1 2018 and has held it in 26 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Citadel Advisors held 5,810,642 shares of ADMA Biologics worth $52.4M as of Q1 2026.
  • Citadel Advisors bought 4,288,072 ADMA Biologics shares in Q1 2026, an estimated $67.7M.
  • ADMA Biologics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1316 holding.
  • Citadel Advisors first reported a position in ADMA Biologics in Q1 2018 and has held it in 26 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.